Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents
КАРДИОЛОГИЯ УЗБЕКИСТАНА 9(1): 28-38
Article 2016 English
Authors
UB
Usman Baber
GG
Gennaro Giustino
SS
Samantha Sartori
Abstract
2 min read
Objectives
This study sought to evaluate: 1) the effect of impaired renal function on long-term clinical outcomes in women undergoing percutaneous coronary intervention (PCI) with drug-eluting stent (DES); and 2) the safety and efficacy of new-generation compared with early-generation DES in women with chronic kidney disease (CKD).
Background
The prevalence and effect of CKD in women undergoing PCI with DES is unclear.
Methods
We pooled patient-level data for women enrolled in 26 randomized trials. The study population was categorized by creatinine clearance (CrCl) <45 ml/min, 45 to 59 ml/min, and ≥60 ml/min. The primary endpoint was the 3-year rate of major adverse cardiovascular events (MACE). Participants for whom baseline creatinine was missing were excluded from the analysis.
Results
Of 4,217 women included in the pooled cohort treated with DES and for whom serum creatinine was available, 603 (14%) had a CrCl <45 ml/min, 811 (19%) had a CrCl 45 to 59 ml/min, and 2,803 (66%) had a CrCl ≥60 ml/min. A significant stepwise gradient in risk for MACE was observed with worsening renal function (26.6% vs. 15.8% vs. 12.9%; p < 0.01). Following multivariable adjustment, CrCl <45 ml/min was independently associated with a higher risk of MACE (adjusted hazard ratio: 1.56; 95% confidence interval: 1.23 to 1.98) and all-cause mortality (adjusted hazard ratio: 2.67; 95% confidence interval: 1.85 to 3.85). Compared with older-generation DES, the use of newer-generation DES was associated with a reduction in the risk of cardiac death, myocardial infarction, or stent thrombosis in women with CKD. The effect of new-generation DES on outcomes was uniform, between women with or without CKD, without evidence of interaction.
Conclusions
Among women undergoing PCI with DES, CKD is a common comorbidity associated with a strong and independent risk for MACE that is durable over 3 years. The benefits of newer-generation DES are uniform in women with or without CKD.
Usman Baber, Giulio Stefanini, Gennaro Giustino, Gregg W. Stone, Martin B. Leon, Samantha Sartori, Melissa Aquino, Philippe Gabríel Steg, Stephan Windecker, William Wijns, Patrick W. Serruys, Marco Valgimigli, Marie‐Claude Morice, Edoardo Camenzind, Giora Weisz, Pieter C. Smits, David E. Kandzari, Clemens von Birgelen, George Dangas, Søren Galatius, Raban Jeger, Takeshi Kimura, Ghada Mikhail, Dipti Itchhaporia, Laxmi S. Mehta, Rebecca Ortega, Hyo-Soo Kim, Adnan Kastrati, Alaide Chieffo, Roxana Mehran
Gennaro Giustino, Usman Baber, Melissa Aquino, Samantha Sartori, Gregg W. Stone, Martin B. Leon, Philippe Généreux, George Dangas, Jaya Chandrasekhar, Takeshi Kimura, Olga Salianski, Giulio Stefanini, Philippe Gabríel Steg, Stephan Windecker, William Wijns, Patrick W. Serruys, Marco Valgimigli, Marie-Claude Morice, Edoardo Camenzind, Giora Weisz, Pieter C. Smits, David E. Kandzari,
Jaya Chandrasekhar, Usman Baber, Samantha Sartori, Giulio Stefanini, Michele Sarin, Birgit Vogel, Serdar Farhan, Edoardo Camenzind, Martin B. Leon, Gregg W. Stone, Patrick W. Serruys, William Wijns, Philippe Gabríel Steg, Giora Weisz, Alaide Chieffo, Adnan Kastrati, Stephan Windecker, Marie‐Claude Morice, Pieter C. Smits, Clemens von Birgelen, Ghada Mikhail, ,
Gennaro Giustino, Ioannis Mastoris, Usman Baber, Samantha Sartori, Gregg W. Stone, Martin B. Leon, Patrick W. Serruys, Adnan Kastrati, Stephan Windecker, Marco Valgimigli, George Dangas, Clemens von Birgelen, Pieter C. Smits, David E. Kandzari, Søren Galatius, William Wijns, Philippe Gabríel Steg, Giulio Stefanini, Melissa Aquino, Marie-Claude Morice, Edoardo Camenzind, Giora Weisz,
Discussion(0)
No comments yet. Be the first to comment.